Continuing Education Credit Information

Course Description

This one-day symposium will provide an update on recent clinical advances in lung cancer. We have seen high impact advances in all aspects of lung cancer management, from detection to diagnosis and treatment. This symposium will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact didactic talks will be delivered by national thought leaders and well-respected faculty in each field. There will be updates on CT screening and smoking cessation, proper use of liquid biopsy, interpretation of molecular testing results and review of modern bronchoscopic interventions. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on proton beam radiation, minimally invasive surgery and immunotherapy as well as an introduction to oligometastatic cancer and its proper management. Sessions with important updates on targeted therapy and immunotherapy will feature recognized experts in the field and there will be a debate over optimal management of metastatic, PD-L1 positive NSCLC. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions and through a case-based format following each session with access to presentation materials for later review.

Learning Objectives

Physicians

- Explain the benefit of CT screening for lung cancer
- Discuss the current application of liquid biopsy (ctDNA analysis)
- Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer
- Discuss management options for patients with oligometastatic non-small cell lung cancer
- Discuss standard targeted agents in use for patients with driverpositive non-small cell lung cancer (including EGFR, ALK, ROS1, RET. NTRK, and MET)
- Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer
- immunotherapy for PD-L1 positive non-small cell lung cancer
- Discuss management of immune-mediated toxicities

Nurses

- Explain the benefit of CT screening for lung cancer
- Discuss the current application of liquid biopsy (ctDNA analysis)
- Explain the role of multidisciplinary care for early-stage/locally advanced non-small cell lung cancer
- Identify nursing strategies for early detection of immune-
- Cite unique toxicities associated with targeted agents used in NSCLC
- Recognize commune immune related adverse events and factors that increase patient risk

Pharmacists

- Discuss standard targeted agents in use for patients with driverpositive non-small cell lung cancer
- Discuss the role of multidisciplinary care for locally advanced non-small cell lung cancer
- Describe the benefit of immunotherapy in the treatment of advanced small cell lung cancer
- Understand the pharmacologic management of immune-mediated adverse events based on current guidelines and evidence

This conference is intended for pulmonologists, medical and radiation oncologists, pathologists, radiologists, nuclear medicine physicians, interventional radiologists, thoracic surgeons, residents, fellows, medical students, physician assistants, nurse practitioners, nurses, pharmacists, allied health professionals, and other members of the healthcare team interested in the diagnosis and treatment of

CE Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical DOINTLY ACCREDITED PROVIDER Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American

 Debate the controversies of immunotherapy alone or chemo-Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation




This activity was planned by and for the healthcare team, and learners will receive 6.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Pharmacists


This curriculum has been approved for 6.5 contact hours by MedStar Health. MedStar Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

The Universal Activity Number for this program is JA4008151-0000-19-026-L01- P. This learning activity is knowledge-based.



| Washington, onferen Washington Marriott Wardman Park cer an 111g 2019 November 16,

For more infromation a CE.MedStarHealth.or



November 16, 2019

Washington Marriott Wardman Park | Washington, D.C.

Course Directors

Stephen V. Liu, MD MedStar Georgetown University Hospital Washington, D.C.

MedStar Georgetown University Hospital MedStar Washington Hospital Center Washington, D.C.

Chul Kim, MD, MPH

MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center

#DCLUNG19

Course Directors

Stephen V. Liu, MD

Director, Thoracic Medical Oncology Director, Phase I Developmental Therapeutics MedStar Georgetown University Hospital Associate Professor, Medicine Georgetown University Medical Center Washington, D.C.

Chul Kim, MD, MPH

Thoracic Medical Oncologist MedStar Georgetown University Hospital Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

Faculty

Eric D. Anderson, MD

Director, Interventional Pulmonology MedStar Georgetown University Hospital Professor, Clinical Medicine Georgetown University Medical Center Washington, D.C.

Simona L. Armanca, PharmD, BCOP

Clinical Pharmacy Specialist MedStar Georgetown University Hospital Washington, D.C.

Joshua Bauml, MD

Assistant Professor, Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA

Hossein Borghaei, DO, MS Chief, Thoracic Medical Oncology Professor, Hematology and Oncology The Gloria and Edmund M. Dunn Chair in Thoracic Oncology Fox Chase Cancer Center Philadelphia, PA

Alexander E. Drilon, MD

Clinical Director, Early Drug Development Service Associate Attending Physician Thoracic Oncology Service Memorial Sloan Kettering Cancer Center New York, NY

Balazs Halmos, MD

Director, Thoracic/Head and Neck Oncology Montefiore Medical Center Professor, Medicine Albert Einstein College of Medicine Bronx, NY

Sushma Jonna, MD

Clinical Fellow Hematology/Oncolog Georgetown Lombard Comprehensive Cancer Center Washington, D.C.

Puja Gaur Khaitan, MD

Director, Esophageal Surgery MedStar Washington Hospital Center Associate Professor, Division of Thoracic Surgery
Georgetown University Medical Center Washington, D.C.

Hira Latif, MD

Chief Fellow, Hematology- Oncology MedStar Washington Hospital Center Washington, D.C.

John F. Lazar, MD

Director, Thoracic Robotic Surgery Thoracic Surgeon MedStar Washington Hospital Center Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

Benjamin P. Levy, MD

Clinical Director, Medical Oncology Thoracic Medical Oncologist Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Associate Professor, Oncology Johns Hopkins University School of Medicine Washington, D.C.

Jessica J. Lin, MD

Medical Oncologist/Hematologist Massachusetts General Hospital Instructor, Medicine Harvard Medical School Boston, MA

Jonathan W. Lischalk, MD

Radiation Oncologist MedStar Georgetown University Hospital Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

Marc Margolis, MD

Thoracic Surgeon MedStar Georgetown University Hospital Washington, D.C.

Eunice A. Ochuonyo MSN, FNP-C

Nurse Practitioner MedStar Georgetown University Hospital Washington, D.C.

Monica Peravali, MD

Medical Oncologist/Hematologist MedStar Washington Hospital Center Washington, D.C.

Michael T. Serzan, MD

Clinical Fellow Hematology/Oncology MedStar Georgetown University Hospital Washington, D.C.

Irina G. Veytsman, MD

Section Director, Hematology/Oncology Medical Oncologist/Hematologist MedStar Washington Hospital Center Washington, D.C.

Jessica S. Wang Memoli, MD

Pulmonary, Critical Care, and Respiratory Services MedStar Washington Hospital Center Washington, D.C

Agenda

Joshua Bauml, MD

Panel Discussion

Lunch and Visit the Exhibits

| Agenda | | | | |
|---|--|---|--|--|
| 8:00 a.m. | Registration and Continental Breakfast | SESSION III: Updates on Targeted Therapy in Lung Cancer Moderator: Chul Kim, MD, MPH | | |
| SESSION 1: Diagnosing Lung Cancer in the Modern Era Moderator: John F. Lazar, MD | | 1:30 p.m. | Case Presentation Sushma R. Jonna, MD | |
| 9;10 a.m. | Case Presentation Hira Latif, MD | 1:40 p.m. | Sequencing Therapies in ALK Positive NSCLC Jessica J. Lin, MD | |
| 9:20 a.m. | The Current Status of CT Screening Eric D. Anderson, MD | 2:00 p.m. | Optimizing Care in EGFR Positive NSCLC Irina Veytsman, MD | |
| 9:40 a.m. | The Evolving Role of Liquid Biopsy in Lung Cancer Benjamin P. Levy, MD | 2:20 p.m. | Evolving Targets Beyond EGFR and ALK Alexander E. Drilon, MD | |
| 10:00 a.m. | Advances in Peripheral Lung Access & Bronchoscopic Interventions | 2:40 p.m. | Panel Discussion | |
| | Jessica S. Wang Memoli, MD | SESSION IV: Advances in Immunotherapy for Lung Cancer Moderator: Stephen V. Liu, MD | | |
| 10:20 a.m. | Panel Discussion | 2:50 p.m. | Case Presentation | |
| 10:30 a.m. | Break and Visit the Exhibits | 2.50 p.m. | Michael T. Serzan, MD | |
| SESSION II: N Advanced Lui Moderator: Puja | Multidisciplinary Management of Locally ng Cancer o G. Khaitan, MD | 3:00 p.m. | Immunotherapy for Small Cell Lung Cancer Stephen V. Liu, MD | |
| 10:50 a.m. | Case Presentation Monica Peravali, MD | 3:20 p.m. | Debate: Managing Advanced PDL1 Positive NSCLC — Monotherapy Balazs Halmos, MD | |
| 11:00 a.m. | Proton Beam Radiation Therapy in Lung Cancer Jonathan W. Lischalk, MD | 3:40 p.m. | Debate: Managing Advanced PDL1 Positive NSCLC — Chemo- | |
| 11:20 a.m. | Surgical Management of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | 4:00 p.m. | Immunotherapy Hossein Borghaei, DO, MS Nursing Perspectives in the | |
| 11:40 a.m. | Marc Margolis, MD Immunotherapy in Resectable or | | Mangement of Immunotherapy Simona Armanca, PharmD, BCOP; Eunice A. Ochuonyo MSN, FNP-C | |
| | Locally Advanced NSCLC Chul Kim, MD, MPH | 4:20 p.m. | Panel Discussion and Challenging Cases | |
| 12:00 p.m. | Managing Oligometastatic NSCLC | | | |

Closing Remarks

Registration Information

| Registration Fees: | |
|----------------------------|-------|
| Physician | \$175 |
| Resident or Fellow | \$100 |
| Physician Assistant | \$100 |
| Nurse Practitioner | \$100 |
| Nurse | \$100 |
| Pharmacist | \$100 |
| Allied Health Professional | \$100 |

Online Registration Preferred

Please visit our secure website at **CE.MedStarHealth.org/Lung** for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at MedStarCMÉ@gmail.com or 202-735-3104.

Cancellation Policy

Cancellations made in writing by October 16, 2019 will be subject to a 50% penalty. No refunds will be given after this date. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for

Please call 202-735-3104 or email MedStarCME@gmail.com if you have any questions or need any additional information.

Venue Information

Washington Marriott Wardman Park

2660 Woodley Road, NW Washington, D.C. 20008 202-328-2000 https://wardmanparkmarriott.com

A block of rooms has been reserved for attendees at the hotel at the discounted rate of \$139 per night (exclusive of taxes and fees). Reserve your room by October 25 to take advantage of this rate. Reservations can be made by calling 1-877-212-5752 or online at http://bit.ly/LungWP

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-735-3104 to notify us of your needs.

